Axsome Therapeutics Announces SYMBRAVO®

Axsome Therapeutics Announces SYMBRAVO®

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a…

Read More

New MTBI Study Looking for Participants

Have you had a head injury and experienced headaches ever since? If so, you might have post-traumatic headache (PTH).  A new MTBI study is assessing the efficacy of a cognitive-behavioral therapy (CBT) program for smartphone or other internet-connected device designed…

Read More